Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Monopar Therapeutics Inc (MNPR).
Monopar Therapeutics Inc. has revealed encouraging preclinical imaging results for their MNPR-101 therapy, which is linked to a therapeutic radioisotope targeting the uPAR system. This breakthrough could potentially be a significant stride in their therapeutic developments, sparking interest among investors and stakeholders in the biopharmaceutical sector.
For detailed information about MNPR stock, go to TipRanks’ Stock Analysis page.